share_log

Getinge launches NICCI - the latest innovation in Advanced Hemodynamic Monitoring

Getinge launches NICCI - the latest innovation in Advanced Hemodynamic Monitoring

Getinger推出NICCI--先進血流動力學監測領域的最新創新
美通社 ·  2020/10/26 21:34

- NICCI is Getinge's latest innovation in Advanced Hemodynamic Monitoring, providing continuous and noninvasive hemodynamic insights to reduce the risk of severe complications for patients with low blood pressure

-NICCI是Getinger在高級血流動力學監測方面的最新創新,提供持續和非侵入性的血流動力學洞察,降低低血壓患者嚴重併發症的風險

GOTHENBURG, Sweden, Oct. 26, 2020 /PRNewswire/ -- Blood pressure is one of the most important variables evaluated during almost every surgical intervention, but recent studies[1] show that fluctuations in blood pressure may be missed due to standard intermittent readings.

瑞典哥德堡,2020年10月26日/美通社/--血壓是幾乎每個手術幹預過程中評估的最重要的變量之一,但最近的研究[1]顯示血壓的波動可能是不及預期預期的,因為標準的間歇性讀數。

These occurring blood pressure drops, called hypotensions, result in complications which can get severe and even life threatening. They can however be reduced by continuous, noninvasive blood pressure monitoring. That's why Getinge launches NICCI, the latest innovation in Advanced Hemodynamic Monitoring, providing continuous and noninvasive hemodynamic insights. It has already been awarded with the Red Dot Award 2020 for its design.

這些發生的血壓下降稱為低血壓,會導致併發症,可能會變得嚴重,甚至危及生命。然而,通過持續的、非侵入性的血壓監測可以減少它們。這就是Getinger推出NICCI的原因,NICCI是先進血流動力學監測領域的最新創新,提供連續和非侵入性的血流動力學洞察。它的設計已經獲得了2020年度紅點獎。

"With NICCI, hemodynamic monitoring has never been easier. While measuring continuously and non-invasively, NICCI provides a complete picture of the patient's individual hemodynamic status - ensuring the medical staff that they never miss a beat," says Clemens Brühl, Head of Product Management Advanced Patient Monitoring at Getinge.

Getinger產品管理高級患者監測部負責人Clemens Bühl表示:“有了NICI,血流動力學監測變得前所未有地簡單。在連續和非侵入性測量的同時,NICI提供了患者個體血流動力學狀態的完整圖景--確保醫務人員不會錯過任何一次預期。”

With dynamic parameters like cardiac index (CI), stroke volume variation (SVV) and pulse pressure variation (PPV) NICCI guides individual treatment decisions for example related to Goal Directed Fluid Therapy (GDFT).

NICI通過心臟指數(CI)、每搏輸出量變化(SVV)和脈壓變化(PPV)等動態參數指導個人的治療決策,例如與目標導向液體療法(GDFT)相關的治療決策。

"It has a sensor that comes in three sizes, containing two finger cuffs that perform an automatically alternating continuous measurement from one finger to the other after no more than an hour. This enables continuous use of NICCI for up to 72 hours," explains Clemens Brühl.

Clemens Brühl解釋説:“它有三種尺寸的傳感器,包含兩個指套,可以在不超過一小時的時間內自動交替連續測量一個手指和另一個手指之間的距離。這使得Nicci可以連續使用長達72小時。”

He adds:

他補充道:

"The easy click mechanism allows a fast setup and there are smart design elements such as an integrated cable storage and quick access keys to allow a simple handling."

輕鬆的點擊機制允許快速設置,並且有智能設計元素,如集成的電纜存儲和快速訪問鍵,以允許簡單的處理。

NICCI is based on the Continous Noninvasive Arterial Pressure Technology (CNAP).

NICI基於連續無創動脈壓技術(CNAP)。

NICCI allows the anesthesiologist to assess the patients' hemodynamic status even before induction of anesthesia and after surgery. Main application area is before, during and after surgery as well as in post-operative care units, but also emergency rooms and cath-labs.

NICI允許麻醉師甚至在麻醉誘導前和手術後評估患者的血流動力學狀態。主要應用領域是術前、術中和術後以及術後護理病房,也包括急診室和導管室。

Learn more about NICCI >>

瞭解有關Nicci的更多信息>>

Discover facts and figures on hypotension >>

瞭解有關低血壓的事實和數據>>

The availability of NICCI depends on regional regulatory approval status. If you have questions, please reach out to your local Getinge representative.

NICI的可用性取決於地區監管批准狀態。如果您有任何問題,請聯繫您當地的Getinger代表。

Source:

資料來源:

[1]  

[1]

CONTACT:

聯繫方式:

Media contact:

媒體聯繫人:

Anna Appelqvist, Vice President Corporate Communications
Phone: +46-(0)10-335-5906
E-mail:   

企業公關副總裁Anna Appelqvist
電話:+46-(0)10-335-5906
電郵:

This information was brought to you by Cision

這條信息是精靈為您帶來的

The following files are available for download:

以下文件可供下載:

Getinge launches NICCI - the latest innovation in Advanced Hemodynamic Monitoring

Getinge NICCI

Getinger推出NICCI--先進血流動力學監測領域的最新創新

格廷格·尼奇

 

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論